New Delhi: Bharat Biotech’s Covaxin, the coronavirus vaccine being developed in collaboration with the Indian Council of Medical Research (ICMR) has been cleared for the third phase of clinical trials.
In its application to the Drugs Controller General of India (DCGI), seeking permission to conduct Phase 3 trials for its vaccine candidate, said that the study would cover 28,500 subjects aged 18 years and above.
“To summarise, the vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus,” Bharat Biotech posted on its website.
